CXCL2 (C-X-C motif chemokine ligand 2) - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)
Gene: CXCL2 (C-X-C motif chemokine ligand 2) Homo sapiens
Analyze
Symbol: CXCL2
Name: C-X-C motif chemokine ligand 2
RGD ID: 735621
HGNC Page HGNC:4603
Description: Predicted to enable CXCR chemokine receptor binding activity and chemokine activity. Involved in antimicrobial humoral immune response mediated by antimicrobial peptide and response to molecule of bacterial origin. Predicted to be located in extracellular region. Predicted to be active in extracellular space. Biomarker of COVID-19 and cystic fibrosis.
Type: protein-coding
RefSeq Status: REVIEWED
Previously known as: C-X-C motif chemokine 2; chemokine (C-X-C motif) ligand 2; CINC-2a; gro-beta; GRO2; GRO2 oncogene; GROb; growth-regulated protein beta; macrophage inflammatory protein 2-alpha; melanoma growth stimulatory activity beta; MGSA beta; MGSA-b; MIP-2a; MIP2; MIP2-alpha; MIP2A; SCYB2
RGD Orthologs
Mouse
Rat
Bonobo
Pig
Alliance Orthologs
More Info more info ...
Allele / Splice: See ClinVar data
Latest Assembly: GRCh38 - Human Genome Assembly GRCh38
NCBI Annotation Information: Note: This gene has been reviewed for its involvement in coronavirus biology, and is involved in immune response or antiviral activity.
Position:
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh38474,097,040 - 74,099,195 (-)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl474,097,040 - 74,099,196 (-)EnsemblGRCh38hg38GRCh38
GRCh37474,962,757 - 74,964,912 (-)NCBIGRCh37GRCh37hg19GRCh37
Build 36475,181,616 - 75,183,861 (-)NCBINCBI36Build 36hg18NCBI36
Build 34475,327,790 - 75,329,927NCBI
Celera472,322,837 - 72,325,084 (-)NCBICelera
Cytogenetic Map4q13.3NCBI
HuRef470,773,657 - 70,775,906 (-)NCBIHuRef
CHM1_1474,998,593 - 75,000,838 (-)NCBICHM1_1
T2T-CHM13v2.0477,440,641 - 77,442,796 (-)NCBIT2T-CHM13v2.0
JBrowse: View Region in Genome Browser (JBrowse)
Model


Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(-)-epigallocatechin 3-gallate  (ISO)
(2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]-1-oxopentyl]-4-methyl-2-piperidinecarboxylic acid  (ISO)
(4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosahexaenoic acid  (ISO)
(E)-cinnamyl alcohol  (ISO)
(R,R,R)-alpha-tocopherol  (ISO)
(S)-nicotine  (EXP)
1,2,4-trimethylbenzene  (ISO)
1,3-benzothiazole-2-thiol  (ISO)
1,4-phenylenediamine  (ISO)
1,7-dimethylxanthine  (ISO)
1-chloro-2,4-dinitrobenzene  (EXP,ISO)
1-naphthyl isothiocyanate  (ISO)
1-nitropyrene  (EXP)
13,14-dihydro-15-ketoprostaglandin D2  (ISO)
15-acetyldeoxynivalenol  (ISO)
17alpha-ethynylestradiol  (ISO)
17beta-estradiol  (EXP,ISO)
17beta-estradiol 3-benzoate  (ISO)
2''-galloylhyperin  (ISO)
2,2',4,4'-Tetrabromodiphenyl ether  (EXP,ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,4,6-trinitrobenzenesulfonic acid  (ISO)
2,4-dibromophenyl 2,4,5-tribromophenyl ether  (EXP,ISO)
2-acetamidofluorene  (ISO)
2-amino-2-deoxy-D-galactopyranose  (ISO)
2-amino-2-deoxy-D-glucopyranose  (ISO)
2-butoxyethanol  (ISO)
2-hydroxypropanoic acid  (EXP,ISO)
2-naphthylamine  (EXP)
2-tert-butylhydroquinone  (EXP)
22-Hydroxycholesterol  (EXP)
3,3',4,4',5-pentachlorobiphenyl  (EXP)
3,7-dihydropurine-6-thione  (ISO)
3-acetyldeoxynivalenol  (ISO)
3-aminobenzamide  (ISO)
3-chloropropane-1,2-diol  (ISO)
3-isobutyl-1-methyl-7H-xanthine  (EXP,ISO)
3-methyladenine  (ISO)
4,4'-diaminodiphenylmethane  (ISO)
4,4'-sulfonyldiphenol  (EXP)
4-(ethoxymethylene)-2-phenyloxazol-5-one  (ISO)
4-hydroxyphenyl retinamide  (EXP,ISO)
4-nitroquinoline N-oxide  (ISO)
5-fluorouracil  (ISO)
5-Isoxazoleacetic acid, 4,5-dihydro-3-(4-hydroxyphenyl)-, methyl ester  (ISO)
6alpha-methylprednisolone  (EXP)
acrolein  (ISO)
Actein  (ISO)
aflatoxin B1  (EXP,ISO)
Aflatoxin G1  (ISO)
aldehydo-D-glucosamine  (ISO)
aldehydo-D-glucose  (ISO)
alpha-amanitin  (ISO)
alpha-hexylcinnamaldehyde  (ISO)
aluminium sulfate (anhydrous)  (ISO)
amiloride  (ISO)
amiodarone  (ISO)
amitrole  (ISO)
amlexanox  (ISO)
ammonium chloride  (ISO)
Ammothamnine  (ISO)
amphibole asbestos  (EXP,ISO)
amphotericin B  (EXP)
ampicillin  (ISO)
andrographolide  (EXP,ISO)
anthocyanin  (ISO)
anthra[1,9-cd]pyrazol-6(2H)-one  (ISO)
antirheumatic drug  (EXP)
argatroban  (ISO)
aripiprazole  (EXP)
arsane  (EXP,ISO)
arsenic atom  (EXP,ISO)
arsenite(3-)  (ISO)
arsenous acid  (EXP)
asbestos  (ISO)
asperentin  (ISO)
ATP  (ISO)
azathioprine  (ISO)
azetidine  (ISO)
Bardoxolone methyl  (EXP,ISO)
benzalkonium chloride  (ISO)
benzene-1,2,4-triol  (EXP)
benzo[a]pyrene  (EXP,ISO)
benzo[a]pyrene diol epoxide I  (EXP)
benzoates  (ISO)
beta-D-glucosamine  (ISO)
beta-eudesmol  (ISO)
beta-lapachone  (EXP)
beta-naphthoflavone  (EXP)
bilirubin IXalpha  (EXP)
bis(2-chloroethyl) sulfide  (EXP,ISO)
bis(2-ethylhexyl) phthalate  (ISO)
bisphenol A  (EXP,ISO)
bisphenol F  (EXP,ISO)
bleomycin A2  (EXP,ISO)
boron nitride  (EXP)
bortezomib  (ISO)
Botulinum toxin type A  (ISO)
Brevianamide A  (ISO)
budesonide  (ISO)
butanal  (EXP)
C60 fullerene  (ISO)
cadmium atom  (EXP,ISO)
cadmium dichloride  (EXP,ISO)
cadmium sulfate  (ISO)
calcitriol  (EXP,ISO)
calcium atom  (EXP)
calcium(0)  (EXP)
cannabidiol  (EXP,ISO)
capsaicin  (ISO)
carbamazepine  (ISO)
carbon nanotube  (EXP,ISO)
carmustine  (EXP)
carrageenan  (ISO)
CGP 52608  (EXP)
chenodeoxycholic acid  (ISO)
chloroethene  (ISO)
chlorothalonil  (EXP)
cholesterol  (EXP)
choline  (ISO)
chondroitin sulfate  (EXP)
cinnamyl alcohol  (ISO)
ciprofloxacin  (ISO)
cirsilineol  (ISO)
cis-caffeic acid  (EXP)
cisplatin  (EXP,ISO)
citral  (ISO)
cobalt atom  (ISO)
cobalt dichloride  (ISO)
copper atom  (EXP,ISO)
copper(0)  (EXP,ISO)
copper(II) sulfate  (EXP,ISO)
cordycepin  (ISO)
corosolic acid  (ISO)
crocidolite asbestos  (EXP,ISO)
crotonaldehyde  (EXP)
curcumin  (EXP,ISO)
cyclophosphamide  (ISO)
cyclosporin A  (EXP,ISO)
D-glucose  (ISO)
dantrolene  (ISO)
decabromodiphenyl ether  (ISO)
Decursin  (ISO)
deoxycholic acid  (ISO)
deoxynivalenol  (EXP,ISO)
desferrioxamine B  (ISO)
dexamethasone  (EXP,ISO)
dextran sulfate  (ISO)
Diallyl sulfide  (ISO)
diallyl trisulfide  (EXP)
diarsenic trioxide  (EXP)
diclofenac  (ISO)
dicloxacillin  (ISO)
diflorasone  (ISO)
dimercaprol  (ISO)
dimethylarsinous acid  (EXP)
dioxygen  (ISO)
disodium selenite  (EXP)
diuron  (ISO)
divanadium pentaoxide  (ISO)
dizocilpine maleate  (ISO)
dobutamine  (ISO)
domperidone  (ISO)
dopexamine  (ISO)
doxorubicin  (EXP)
edaravone  (ISO)
elemental selenium  (EXP)
emodin  (ISO)
endosulfan  (ISO)
enflurane  (ISO)
ethanol  (ISO)
ethylene glycol dimethacrylate  (ISO)
excitatory amino acid agonist  (ISO)
ferroheme b  (ISO)
flavonoids  (ISO)
flucloxacillin  (ISO)
flutamide  (ISO)
fomepizole  (ISO)
fulvestrant  (ISO)
fumonisin B1  (EXP)
furan  (ISO)
Fusarenone X  (ISO)
gadolinium trichloride  (ISO)
gemcitabine  (EXP)
gentamycin  (ISO)
geranial  (ISO)
glucose  (ISO)
gold atom  (ISO)
gold(0)  (ISO)
graphene oxide  (ISO)
graphite  (ISO)
halothane  (ISO)
heme b  (ISO)
heparin  (ISO)
hexadecanoic acid  (EXP)
hydrogen chloride  (ISO)
hydrogen peroxide  (EXP,ISO)
ibuprofen  (ISO)
imidurea  (ISO)
indometacin  (EXP,ISO)
iron atom  (ISO)
iron trichloride  (ISO)
iron(0)  (ISO)
iron(2+) sulfate (anhydrous)  (ISO)
isoeugenol  (ISO)
isoflurane  (ISO)
L-methionine  (ISO)
lipopolysaccharide  (EXP,ISO)
lipoteichoic acid  (ISO)
lipoxin A4  (ISO)
lithocholic acid  (ISO)
LY294002  (ISO)
lycopene  (ISO)
manganese atom  (EXP,ISO)
manganese(0)  (EXP,ISO)
manganese(II) chloride  (EXP,ISO)
manganese(II) sulfate  (ISO)
maslinic acid  (ISO)
mercaptopurine  (ISO)
mercury dichloride  (ISO)
metacetamol  (ISO)
metformin  (ISO)
methamphetamine  (EXP,ISO)
methimazole  (ISO)
methotrexate  (EXP,ISO)
methyl methacrylate  (ISO)
methyl salicylate  (ISO)
methylmercury chloride  (ISO)
metoclopramide  (ISO)
microcystin-LR  (ISO)
mifepristone  (ISO)
Muraglitazar  (ISO)
mycophenolic acid  (ISO)
mycotoxin  (ISO)
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine  (EXP)
N-acetyl-L-cysteine  (EXP,ISO)
N1'-[2-[[5-[(dimethylamino)methyl]-2-furanyl]methylthio]ethyl]-N1-methyl-2-nitroethene-1,1-diamine  (ISO)
naphthalene  (ISO)
naphthalenes  (ISO)
naproxen  (ISO)
naringin  (ISO)
neocuproine  (ISO)
neoechinulin A  (ISO)
nickel atom  (EXP,ISO)
nickel dichloride  (EXP,ISO)
nickel sulfate  (EXP,ISO)
nicotine  (EXP)
nitrofen  (ISO)
nitrogen dioxide  (ISO)
Nivalenol  (ISO)
nonivamide  (ISO)
o-anisidine  (EXP)
obeticholic acid  (ISO)
olaparib  (ISO)
oleanolic acid  (ISO)
oleic acid  (EXP)
oligopeptide  (ISO)
oxaliplatin  (ISO)
ozone  (EXP,ISO)
p-menthan-3-ol  (ISO)
paracetamol  (EXP,ISO)
paraquat  (EXP,ISO)
parthenolide  (ISO)
pentanal  (EXP)
Pentoxifylline  (ISO)
peptidoglycan  (ISO)
perfluorooctane-1-sulfonic acid  (EXP)
perfluorooctanoic acid  (EXP)
phalloidin  (ISO)
phenanthridone  (ISO)
phenobarbital  (ISO)
phenytoin  (ISO)
phorbol 13-acetate 12-myristate  (ISO)
pioglitazone  (ISO)
pirinixic acid  (ISO)
piroxicam  (EXP)
poly(I:C)  (ISO)
polymyxin B2  (EXP)
pravastatin  (ISO)
prednisolone  (EXP)
Primycin  (EXP)
procymidone  (ISO)
progesterone  (EXP,ISO)
propan-2-ol  (ISO)
propanal  (EXP)
prostaglandin D2  (ISO)
prostaglandin E1  (ISO)
purine-6-thiol  (ISO)
pyrrolidine dithiocarbamate  (ISO)
quartz  (ISO)
quercetin  (EXP,ISO)
quercetin 3-O-beta-D-glucofuranoside  (ISO)
quercetin 3-O-beta-D-glucopyranoside  (ISO)
quinomethionate  (EXP)
rac-lactic acid  (EXP,ISO)
raloxifene  (ISO)
ranitidine  (ISO)
reactive oxygen species  (EXP,ISO)
resolvin D1  (ISO)
resolvin D2  (ISO)
resorcinol  (EXP)
resveratrol  (EXP,ISO)
ritonavir  (EXP)
Roridin A  (ISO)
rotenone  (ISO)
ryanodine  (ISO)
S-(1,2-dichlorovinyl)-L-cysteine  (EXP)
S-butyl-DL-homocysteine (S,R)-sulfoximine  (ISO)
salicylic acid  (ISO)
SB 203580  (EXP,ISO)
SB 431542  (ISO)
selenium atom  (EXP)
serpentine asbestos  (EXP)
sevoflurane  (ISO)
silicon dioxide  (EXP,ISO)
silver atom  (ISO)
silver(0)  (ISO)
simvastatin  (ISO)
sodium arsenate  (ISO)
sodium arsenite  (EXP,ISO)
sodium aurothiomalate  (EXP)
sodium dodecyl sulfate  (ISO)
sterigmatocystin  (ISO)
styrene  (ISO)
succimer  (ISO)
sulfadimethoxine  (ISO)
sulforaphane  (EXP)
sumatriptan  (ISO)
tamoxifen  (ISO)
tauro-beta-muricholic acid  (ISO)
taurocholic acid  (ISO)
temozolomide  (EXP)
tert-butyl hydroperoxide  (EXP)
Tesaglitazar  (ISO)
testosterone  (ISO)
tetrachloromethane  (ISO)
tetradecane  (ISO)
thapsigargin  (EXP)
thioacetamide  (ISO)
thiram  (EXP)
Tiron  (ISO)
titanium dioxide  (ISO)
TMC-120A  (ISO)
toluene 2,4-diisocyanate  (ISO)
topotecan  (ISO)
trans-caffeic acid  (EXP)
trans-isoeugenol  (ISO)
triadimefon  (ISO)
trichostatin A  (EXP)
triclosan  (ISO)
trimellitic anhydride  (ISO)
Triptolide  (ISO)
troglitazone  (EXP,ISO)
tropisetron  (ISO)
trovafloxacin  (ISO)
tungsten  (ISO)
tunicamycin  (EXP)
UDP  (ISO)
undecane  (ISO)
ursodeoxycholic acid  (ISO)
ursolic acid  (ISO)
valproic acid  (EXP)
vanadium atom  (ISO)
vanadium(0)  (ISO)
vanadyl sulfate  (EXP)
vinclozolin  (ISO)
vitamin D  (ISO)
wortmannin  (EXP,ISO)
XL147  (ISO)
zaragozic acid A  (ISO)
zinc atom  (ISO)
zinc oxide  (ISO)
zinc protoporphyrin  (ISO)
zinc sulfate  (EXP,ISO)
zinc(0)  (ISO)
zoledronic acid  (EXP)

Gene Ontology Annotations     Click to see Annotation Detail View

Cellular Component
extracellular region  (IEA,TAS)
extracellular space  (IBA,IEA,ISO,TAS)

Molecular Function

Molecular Pathway Annotations     Click to see Annotation Detail View
References

References - curated
# Reference Title Reference Citation
1. Role of cytokine-induced neutrophil chemoattractant-2 (CINC-2) alpha in a rat model of chronic bronchopulmonary infections with Pseudomonas aeruginosa. Amano H, etal., Cytokine. 2000 Nov;12(11):1662-8.
2. Treating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infection. Bauer CM, etal., PLoS One. 2010 Oct 12;5(10):e13251.
3. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Blanco-Melo D, etal., Cell. 2020 May 28;181(5):1036-1045.e9. doi: 10.1016/j.cell.2020.04.026. Epub 2020 May 15.
4. Ischemia-reperfusion of rat myocardium activates nuclear factor-KappaB and induces neutrophil infiltration via lipopolysaccharide-induced CXC chemokine. Chandrasekar B, etal., Circulation. 2001 May 8;103(18):2296-302.
5. Apocynin attenuates ventilator-induced lung injury in an isolated and perfused rat lung model. Chiang CH, etal., Intensive Care Med. 2011 May 27.
6. Lung and liver injury following hepatic ischemia/reperfusion in the rat is increased by exogenous lipopolysaccharide which also increases hepatic TNF production in vivo and in vitro. Colletti LM and Green M, Shock. 2001 Oct;16(4):312-9.
7. The ratio of ELR+ to ELR- CXC chemokines affects the lung and liver injury following hepatic ischemia/ reperfusion in the rat. Colletti LM, etal., Hepatology. 2000 Feb;31(2):435-45.
8. [Role of early growth response factor-1 signal pathway in acute intrahepatic cholestatic hepatic injury in rats]. Ding Y, etal., Zhonghua Gan Zang Bing Za Zhi. 2008 Mar;16(3):215-9.
9. Impairment of leukocyte trafficking in a murine pleuritis model by IL-4 and IL-10. Fine JS, etal., Inflammation. 2003 Aug;27(4):161-74.
10. Irsogladine maleate regulates neutrophil migration and E-cadherin expression in gingival epithelium stimulated by Aggregatibacter actinomycetemcomitans. Fujita T, etal., Biochem Pharmacol. 2010 May 15;79(10):1496-505. Epub 2010 Jan 22.
11. Characterization of the inflammatory response during acute and post-acute phases after severe burn. Gauglitz GG, etal., Shock. 2008 Nov;30(5):503-7.
12. GOAs Human GO annotations GOA_HUMAN data from the GO Consortium
13. Differential host gene responses in mice infected with two highly pathogenic avian influenza viruses of subtype H5N1 isolated from wild birds in Thailand. Hayashi T, etal., Virology. 2011 Mar 30;412(1):9-18. Epub 2011 Jan 19.
14. Mechanism of estrogen-mediated intestinal protection following trauma-hemorrhage: p38 MAPK-dependent upregulation of HO-1. Hsu JT, etal., Am J Physiol Regul Integr Comp Physiol. 2008 Jun;294(6):R1825-31. Epub 2008 Apr 23.
15. Platonin mitigates acute lung injury induced by bilateral lower limb ischemia-reperfusion in rats. Hsu KY, etal., J Surg Res. 2011 May 15;167(2):e255-62. Epub 2010 Apr 24.
16. Vitamin A and retinoic acid act synergistically to increase lung retinyl esters during normoxia and reduce hyperoxic lung injury in newborn mice. James ML, etal., Pediatr Res. 2010 Jun;67(6):591-7.
17. Transcriptional profiling of lipopolysaccharide-induced acute lung injury. Jeyaseelan S, etal., Infect Immun. 2004 Dec;72(12):7247-56.
18. Protection against sepsis-induced lung injury by selective inhibition of protein kinase C-delta (delta-PKC). Kilpatrick LE, etal., J Leukoc Biol. 2011 Jan;89(1):3-10. Epub 2010 Aug 19.
19. Role of neutrophils and NADPH phagocyte oxidase in host defense against respiratory infection with virulent Francisella tularensis in mice. KuoLee R, etal., Microbes Infect. 2011 May;13(5):447-56. Epub 2011 Jan 26.
20. Blockade of cysteine-rich protein 61 attenuates renal inflammation and fibrosis after ischemic kidney injury. Lai CF, etal., Am J Physiol Renal Physiol. 2014 Sep 1;307(5):F581-92. doi: 10.1152/ajprenal.00670.2013. Epub 2014 Jun 11.
21. The role of keratinocyte-derived chemokine in hemorrhage-induced acute lung injury in mice. Lee BH, etal., J Korean Med Sci. 2009 Oct;24(5):775-81. Epub 2009 Sep 23.
22. Effect of glucocorticoid pretreatment on oxidative liver injury and survival in jaundiced rats with endotoxin cholangitis. Lee CW, etal., World J Surg. 2006 Dec;30(12):2217-26. doi: 10.1007/s00268-006-0143-0.
23. Effect of compound IMMLG5521, a novel coumarin derivative, on carrageenan-induced pleurisy in rats. Li ZP, etal., Eur J Pharmacol. 2011 Jul 1;661(1-3):118-23. Epub 2011 Apr 27.
24. In mice, tuberculosis progression is associated with intensive inflammatory response and the accumulation of Gr-1 cells in the lungs. Lyadova IV, etal., PLoS One. 2010 May 4;5(5):e10469.
25. Low intensity laser therapy (LILT) in vivo acts on the neutrophils recruitment and chemokines/cytokines levels in a model of acute pulmonary inflammation induced by aerosol of lipopolysaccharide from Escherichia coli in rat. Mafra de Lima F, etal., J Photochem Photobiol B. 2010 Dec 2;101(3):271-8. Epub 2010 Jul 27.
26. CXCR2 mediates NADPH oxidase-independent neutrophil extracellular trap formation in cystic fibrosis airway inflammation. Marcos V, etal., Nat Med. 2010 Sep;16(9):1018-23. Epub 2010 Sep 5.
27. Rat coronaviruses infect rat alveolar type I epithelial cells and induce expression of CXC chemokines. Miura TA, etal., Virology. 2007 Dec 20;369(2):288-98. Epub 2007 Sep 5.
28. Novel experimental Pseudomonas aeruginosa lung infection model mimicking long-term host-pathogen interactions in cystic fibrosis. Moser C, etal., APMIS. 2009 Feb;117(2):95-107.
29. Activation of nuclear factor kappa B and cytokine imbalance in experimental alcoholic liver disease in the rat. Nanji AA, etal., Hepatology. 1999 Oct;30(4):934-43.
30. Mechanisms of acute inflammatory lung injury induced by abdominal sepsis. Neumann B, etal., Int Immunol. 1999 Feb;11(2):217-27.
31. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
32. Biomarkers of acute respiratory allergen exposure: screening for sensitization potential. Pucheu-Haston CM, etal., Toxicol Appl Pharmacol. 2010 Apr 15;244(2):144-55. Epub 2010 Jan 4.
33. Superimposed gastric aspiration increases the severity of inflammation and permeability injury in a rat model of lung contusion. Raghavendran K, etal., J Surg Res. 2009 Aug;155(2):273-82. Epub 2008 Sep 16.
34. Preliminary investigation of a mice model of Klebsiella pneumoniae subsp. ozaenae induced pneumonia. Renois F, etal., Microbes Infect. 2011 Jun 30.
35. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
36. The temporal expression, cellular localization, and inhibition of the chemokines MIP-2 and MCP-1 after traumatic brain injury in the rat. Rhodes JK, etal., J Neurotrauma. 2009 Apr;26(4):507-25.
37. A rat model of picornavirus-induced airway infection and inflammation. Rosenthal LA, etal., Virol J. 2009 Aug 11;6:122.
38. Soot nanoparticles promote biotransformation, oxidative stress, and inflammation in murine lungs. Rouse RL, etal., Am J Respir Cell Mol Biol. 2008 Aug;39(2):198-207. Epub 2008 Mar 26.
39. The murine neutrophil-chemoattractant chemokines LIX, KC, and MIP-2 have distinct induction kinetics, tissue distributions, and tissue-specific sensitivities to glucocorticoid regulation in endotoxemia. Rovai LE, etal., J Leukoc Biol. 1998 Oct;64(4):494-502.
40. Protection from pulmonary ischemia-reperfusion injury by adenosine A2A receptor activation. Sharma AK, etal., Respir Res. 2009 Jun 26;10:58.
41. Hepatic interferon regulatory factor 8 expression mediates liver ischemia/reperfusion injury in mice. Shi G, etal., Biochem Pharmacol. 2021 Oct;192:114728. doi: 10.1016/j.bcp.2021.114728. Epub 2021 Aug 13.
42. Role of CFTR expressed by neutrophils in modulating acute lung inflammation and injury in mice. Su X, etal., Inflamm Res. 2011 Jul;60(7):619-32. Epub 2011 Feb 8.
43. Chemokine-dependent neutrophil recruitment in a murine model of Legionella pneumonia: potential role of neutrophils as immunoregulatory cells. Tateda K, etal., Infect Immun. 2001 Apr;69(4):2017-24.
44. The protective function of neutrophil elastase inhibitor in liver ischemia/reperfusion injury. Uchida Y, etal., Transplantation. 2010 May 15;89(9):1050-6.
45. Role of the Fas/FasL system in a model of RSV infection in mechanically ventilated mice. van den Berg E, etal., Am J Physiol Lung Cell Mol Physiol. 2011 Jul 8.
46. Elevated levels of macrophage inflammatory protein 2 in severe murine peritonitis increase neutrophil recruitment and mortality. Walley KR, etal., Infect Immun. 1997 Sep;65(9):3847-51.
47. Delay of LPS-induced acute lung injury resolution by soluble immune complexes is neutrophil dependent. Wu CL, etal., Shock. 2009 Sep;32(3):276-85.
48. Correlation of macrophage inflammatory protein-2 expression and brain edema in rats after intracerebral hemorrhage. Wu H, etal., Int J Clin Exp Pathol. 2009;2(1):83-90. Epub 2008 Jun 2.
49. [Effects of N-acetylcysteine on mRNA expression of monocyte chemotactic protein and macrophage inflammatory protein 2 in acute necrotizing pancreatitis: experiment with rats] Xu CF, etal., Zhonghua Yi Xue Za Zhi. 2008 Mar 11;88(10):711-5.
50. Akt pathway is required for oestrogen-mediated attenuation of lung injury in a rodent model of cerulein-induced acute pancreatitis. Yang SJ, etal., Injury. 2011 Jul;42(7):638-42. Epub 2010 Aug 14.
51. Dysregulated macrophage-inflammatory protein-2 expression drives illness in bacterial superinfection of influenza. Zavitz CC, etal., J Immunol. 2010 Feb 15;184(4):2001-13. Epub 2010 Jan 11.
52. A novel ELR-CXC chemokine antagonist reduces intestinal ischemia reperfusion-induced mortality, and local and remote organ injury. Zhao X, etal., J Surg Res. 2010 Aug;162(2):264-73. Epub 2009 Jun 6.
53. Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients. Zhou Z, etal., Cell Host Microbe. 2020 Jun 10;27(6):883-890.e2. doi: 10.1016/j.chom.2020.04.017. Epub 2020 May 4.
Additional References at PubMed
PMID:1906501   PMID:2078213   PMID:2129556   PMID:2201751   PMID:2217207   PMID:2341726   PMID:2643119   PMID:2834384   PMID:7864661   PMID:8702798   PMID:9260277   PMID:9277410  
PMID:9843467   PMID:9873037   PMID:10600366   PMID:10725737   PMID:10928473   PMID:11134351   PMID:11559650   PMID:12419803   PMID:12477932   PMID:12508094   PMID:12556377   PMID:12892904  
PMID:12949249   PMID:15489334   PMID:15614130   PMID:16421598   PMID:16697212   PMID:17466952   PMID:17703412   PMID:17944017   PMID:17999991   PMID:18191274   PMID:18240029   PMID:18275857  
PMID:18322244   PMID:18577758   PMID:18624398   PMID:18835392   PMID:19258923   PMID:19369450   PMID:19435811   PMID:19912257   PMID:20056178   PMID:20162422   PMID:20185584   PMID:20237496  
PMID:21145461   PMID:21220697   PMID:21314817   PMID:21630055   PMID:21677836   PMID:21738478   PMID:21738479   PMID:21873635   PMID:21988832   PMID:22056994   PMID:22615136   PMID:22770218  
PMID:22771802   PMID:23021568   PMID:23128233   PMID:23225384   PMID:23372021   PMID:23554905   PMID:23867815   PMID:23904157   PMID:24098805   PMID:24667918   PMID:25085744   PMID:25682075  
PMID:25708728   PMID:25801245   PMID:25802102   PMID:26063953   PMID:26345899   PMID:26888013   PMID:27117207   PMID:27580404   PMID:27721403   PMID:28381538   PMID:28765918   PMID:28928065  
PMID:29520695   PMID:30259595   PMID:30293547   PMID:30564899   PMID:31292171   PMID:31451648   PMID:31617252   PMID:32267022   PMID:32439934   PMID:32452055   PMID:32643867   PMID:32988253  
PMID:33010041   PMID:33571109   PMID:33793061   PMID:33807899   PMID:33961781   PMID:34085699   PMID:34115261   PMID:34474677   PMID:34607953   PMID:35541899   PMID:36073801   PMID:36281171  
PMID:36398464   PMID:36577281   PMID:38010448  


Genomics

Comparative Map Data
CXCL2
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh38474,097,040 - 74,099,195 (-)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl474,097,040 - 74,099,196 (-)EnsemblGRCh38hg38GRCh38
GRCh37474,962,757 - 74,964,912 (-)NCBIGRCh37GRCh37hg19GRCh37
Build 36475,181,616 - 75,183,861 (-)NCBINCBI36Build 36hg18NCBI36
Build 34475,327,790 - 75,329,927NCBI
Celera472,322,837 - 72,325,084 (-)NCBICelera
Cytogenetic Map4q13.3NCBI
HuRef470,773,657 - 70,775,906 (-)NCBIHuRef
CHM1_1474,998,593 - 75,000,838 (-)NCBICHM1_1
T2T-CHM13v2.0477,440,641 - 77,442,796 (-)NCBIT2T-CHM13v2.0
Cxcl2
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm39591,051,758 - 91,053,797 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl591,051,730 - 91,053,797 (+)EnsemblGRCm39 Ensembl
GRCm38590,903,899 - 90,905,938 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl590,903,871 - 90,905,938 (+)EnsemblGRCm38mm10GRCm38
MGSCv37591,332,925 - 91,334,964 (+)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv36591,979,099 - 91,981,138 (+)NCBIMGSCv36mm8
Celera589,048,217 - 89,050,256 (+)NCBICelera
Cytogenetic Map5E1NCBI
cM Map544.78NCBI
Cxcl2
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81417,465,210 - 17,467,255 (-)NCBIGRCr8
mRatBN7.21417,181,030 - 17,183,075 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1417,181,062 - 17,183,075 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1417,181,873 - 17,183,917 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01418,500,809 - 18,502,853 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01417,192,924 - 17,194,968 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01418,731,346 - 18,733,391 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1418,731,378 - 18,733,391 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01418,640,312 - 18,642,357 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41418,677,129 - 18,679,175 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11418,677,128 - 18,679,175 (-)NCBI
Celera1416,558,112 - 16,560,157 (-)NCBICelera
Cytogenetic Map14p22NCBI
LOC100974886
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
NHGRI_mPanPan1-v2355,960,804 - 55,963,432 (+)NCBINHGRI_mPanPan1-v2
NHGRI_mPanPan1456,150,028 - 56,152,424 (+)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v0450,092,989 - 50,095,541 (+)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.1455,925,562 - 55,927,809 (+)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl455,925,562 - 55,986,555 (+)Ensemblpanpan1.1panPan2
CXCL2
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl870,157,214 - 70,159,138 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.1870,157,253 - 70,159,145 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.2874,310,094 - 74,311,988 (+)NCBISscrofa10.2Sscrofa10.2susScr3

Variants

.
Variants in CXCL2
5 total Variants

Clinical Variants
Name Type Condition(s) Position(s) Clinical significance
GRCh38/hg38 4q13.3-21.21(chr4:71128874-78099088)x3 copy number gain See cases [RCV000051774] Chr4:71128874..78099088 [GRCh38]
Chr4:71994591..79020242 [GRCh37]
Chr4:72213455..79239266 [NCBI36]
Chr4:4q13.3-21.21		 pathogenic
GRCh38/hg38 4q12-22.3(chr4:51831622-97505618)x3 copy number gain See cases [RCV000051772] Chr4:51831622..97505618 [GRCh38]
Chr4:52697788..98426769 [GRCh37]
Chr4:52392545..98645792 [NCBI36]
Chr4:4q12-22.3		 pathogenic
GRCh38/hg38 4q13.2-21.23(chr4:67869564-85517308)x1 copy number loss Developmental Delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000053294]|Developmental delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000053294]|See cases [RCV000053294] Chr4:67869564..85517308 [GRCh38]
Chr4:68735282..86438461 [GRCh37]
Chr4:68417877..86657485 [NCBI36]
Chr4:4q13.2-21.23		 pathogenic
GRCh38/hg38 4q13.3-21.22(chr4:71079179-81802208)x1 copy number loss Developmental Delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000053295]|Developmental delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000053295]|See cases [RCV000053295] Chr4:71079179..81802208 [GRCh38]
Chr4:71944896..82723361 [GRCh37]
Chr4:72163760..82942385 [NCBI36]
Chr4:4q13.3-21.22		 pathogenic
GRCh38/hg38 4q13.3-22.1(chr4:74031395-90421127)x1 copy number loss Developmental Delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000053296]|Developmental delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000053296]|See cases [RCV000053296] Chr4:74031395..90421127 [GRCh38]
Chr4:74897112..91342278 [GRCh37]
Chr4:75115976..91561301 [NCBI36]
Chr4:4q13.3-22.1		 pathogenic
GRCh38/hg38 4q13.3(chr4:74097483-75266770)x1 copy number loss See cases [RCV000136998] Chr4:74097483..75266770 [GRCh38]
Chr4:74963200..76191980 [GRCh37]
Chr4:75182064..76411004 [NCBI36]
Chr4:4q13.3		 uncertain significance
GRCh38/hg38 4q13.2-13.3(chr4:67799665-74240920)x1 copy number loss See cases [RCV000137622] Chr4:67799665..74240920 [GRCh38]
Chr4:68665383..75106637 [GRCh37]
Chr4:68347978..75325501 [NCBI36]
Chr4:4q13.2-13.3		 likely pathogenic
GRCh38/hg38 4q13.3-21.3(chr4:72262258-86002147)x3 copy number gain See cases [RCV000138312] Chr4:72262258..86002147 [GRCh38]
Chr4:73127975..86923300 [GRCh37]
Chr4:73346839..87142324 [NCBI36]
Chr4:4q13.3-21.3		 pathogenic
GRCh38/hg38 4q13.2-22.3(chr4:68686088-95294456)x3 copy number gain See cases [RCV000143458] Chr4:68686088..95294456 [GRCh38]
Chr4:69551806..96215607 [GRCh37]
Chr4:69234401..96434630 [NCBI36]
Chr4:4q13.2-22.3		 pathogenic
GRCh37/hg19 4p16.3-q35.2(chr4:12440-190904441)x3 copy number gain See cases [RCV000446653] Chr4:12440..190904441 [GRCh37]
Chr4:4p16.3-q35.2		 pathogenic
GRCh37/hg19 4q13.3(chr4:74846849-74964907)x3 copy number gain See cases [RCV000448541] Chr4:74846849..74964907 [GRCh37]
Chr4:4q13.3		 likely benign
GRCh37/hg19 4q13.1-21.1(chr4:66017575-76772947)x1 copy number loss See cases [RCV000510445] Chr4:66017575..76772947 [GRCh37]
Chr4:4q13.1-21.1		 pathogenic
GRCh37/hg19 4p16.3-q35.2(chr4:68346-190957473) copy number gain See cases [RCV000510453] Chr4:68346..190957473 [GRCh37]
Chr4:4p16.3-q35.2		 pathogenic
GRCh37/hg19 4p16.3-q35.2(chr4:68346-190957473)x3 copy number gain See cases [RCV000512241] Chr4:68346..190957473 [GRCh37]
Chr4:4p16.3-q35.2		 pathogenic
GRCh37/hg19 4q13.3(chr4:73952783-75261407)x3 copy number gain not provided [RCV000682420] Chr4:73952783..75261407 [GRCh37]
Chr4:4q13.3		 uncertain significance
GRCh37/hg19 4q13.3-21.1(chr4:74890695-77318961)x1 copy number loss not provided [RCV000682421] Chr4:74890695..77318961 [GRCh37]
Chr4:4q13.3-21.1		 uncertain significance
GRCh37/hg19 4q13.3(chr4:74774372-75110540)x3 copy number gain not provided [RCV000743704] Chr4:74774372..75110540 [GRCh37]
Chr4:4q13.3		 benign
GRCh37/hg19 4q13.3(chr4:74785503-74987870)x3 copy number gain not provided [RCV000743705] Chr4:74785503..74987870 [GRCh37]
Chr4:4q13.3		 benign
GRCh37/hg19 4q13.3(chr4:74811802-75110540)x3 copy number gain not provided [RCV000743706] Chr4:74811802..75110540 [GRCh37]
Chr4:4q13.3		 benign
GRCh37/hg19 4p16.3-q35.2(chr4:49450-190963766)x3 copy number gain not provided [RCV000743156] Chr4:49450..190963766 [GRCh37]
Chr4:4p16.3-q35.2		 pathogenic
GRCh37/hg19 4p16.3-q35.2(chr4:11525-191028879)x3 copy number gain not provided [RCV000743147] Chr4:11525..191028879 [GRCh37]
Chr4:4p16.3-q35.2		 pathogenic
GRCh37/hg19 4p16.3-q35.2(chr4:49450-190915650)x3 copy number gain not provided [RCV000743155] Chr4:49450..190915650 [GRCh37]
Chr4:4p16.3-q35.2		 pathogenic
GRCh37/hg19 4q13.2-21.21(chr4:68950363-79738598)x1 copy number loss not provided [RCV001005553] Chr4:68950363..79738598 [GRCh37]
Chr4:4q13.2-21.21		 pathogenic
GRCh37/hg19 4q13.3-21.23(chr4:72680879-86426232)x1 copy number loss not provided [RCV001005556] Chr4:72680879..86426232 [GRCh37]
Chr4:4q13.3-21.23		 pathogenic
GRCh37/hg19 4q13.3-21.1(chr4:71561780-78304341)x1 copy number loss not provided [RCV000846231] Chr4:71561780..78304341 [GRCh37]
Chr4:4q13.3-21.1		 pathogenic
GRCh37/hg19 4q13.3(chr4:74935971-75589619)x3 copy number gain not provided [RCV000846136] Chr4:74935971..75589619 [GRCh37]
Chr4:4q13.3		 uncertain significance
NM_002089.4(CXCL2):c.88C>G (p.Arg30Gly) single nucleotide variant not specified [RCV004305567] Chr4:74099033 [GRCh38]
Chr4:74964750 [GRCh37]
Chr4:4q13.3		 uncertain significance
GRCh38/hg38 4q12-21.1(chr4:51891814-76009719)x1 copy number loss Piebaldism [RCV001420508] Chr4:51891814..76009719 [GRCh38]
Chr4:4q12-21.1		 pathogenic
GRCh37/hg19 4q13.2-21.22(chr4:68242784-82991431)x3 copy number gain not provided [RCV000845944] Chr4:68242784..82991431 [GRCh37]
Chr4:4q13.2-21.22		 pathogenic
GRCh37/hg19 4q13.3-21.3(chr4:71412409-87920784)x1 copy number loss See cases [RCV001263040] Chr4:71412409..87920784 [GRCh37]
Chr4:4q13.3-21.3		 pathogenic
GRCh37/hg19 4q12-31.21(chr4:52866944-143582507)x3 copy number gain not provided [RCV001827738] Chr4:52866944..143582507 [GRCh37]
Chr4:4q12-31.21		 pathogenic
GRCh37/hg19 4q13.3-21.21(chr4:73055313-80083154) copy number loss not specified [RCV002053427] Chr4:73055313..80083154 [GRCh37]
Chr4:4q13.3-21.21		 pathogenic
NC_000004.12:g.67833055_82716065del deletion See cases [RCV003313802] Chr4:67833055..82716065 [GRCh38]
Chr4:4q13.2-21.22		 pathogenic
NM_002089.4(CXCL2):c.88C>T (p.Arg30Trp) single nucleotide variant not specified [RCV004176856] Chr4:74099033 [GRCh38]
Chr4:74964750 [GRCh37]
Chr4:4q13.3		 uncertain significance
GRCh37/hg19 4q13.3-21.1(chr4:74958697-76341496)x1 copy number loss not provided [RCV003485424] Chr4:74958697..76341496 [GRCh37]
Chr4:4q13.3-21.1		 uncertain significance
GRCh37/hg19 4q13.2-13.3(chr4:69146217-75500577)x1 copy number loss not provided [RCV003485422] Chr4:69146217..75500577 [GRCh37]
Chr4:4q13.2-13.3		 pathogenic
GRCh37/hg19 4q13.3-21.21(chr4:74822261-79345650)x1 copy number loss not specified [RCV003986507] Chr4:74822261..79345650 [GRCh37]
Chr4:4q13.3-21.21		 uncertain significance
NM_002089.4(CXCL2):c.22G>A (p.Ala8Thr) single nucleotide variant not specified [RCV004367572] Chr4:74099099 [GRCh38]
Chr4:74964816 [GRCh37]
Chr4:4q13.3		 likely benign
GRCh37/hg19 4p12-q35.2(chr4:45455621-191003541)x3 copy number gain not provided [RCV003885507] Chr4:45455621..191003541 [GRCh37]
Chr4:4p12-q35.2		 pathogenic
NM_002089.4(CXCL2):c.226G>A (p.Ala76Thr) single nucleotide variant not specified [RCV004616189] Chr4:74098683 [GRCh38]
Chr4:74964400 [GRCh37]
Chr4:4q13.3		 uncertain significance
NM_002089.4(CXCL2):c.149A>G (p.Gln50Arg) single nucleotide variant not specified [RCV004616190] Chr4:74098874 [GRCh38]
Chr4:74964591 [GRCh37]
Chr4:4q13.3		 uncertain significance
NM_002089.4(CXCL2):c.50G>C (p.Arg17Pro) single nucleotide variant not specified [RCV004367573] Chr4:74099071 [GRCh38]
Chr4:74964788 [GRCh37]
Chr4:4q13.3		 uncertain significance
miRNA Target Status

Confirmed Target Of
miRNA GeneMature miRNAMethod NameResult TypeData TypeSupport TypePMID
MIR126hsa-miR-126-3pOncomiRDBexternal_infoNANA23449143
MIR126hsa-miR-126-5pOncomiRDBexternal_infoNANA23449143

Predicted Target Of
Summary Value
Count of predictions:469
Count of miRNA genes:367
Interacting mature miRNAs:383
Transcripts:ENST00000296031, ENST00000508487, ENST00000510048
Prediction methods:Miranda, Rnahybrid
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (GRCh38)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
407017970GWAS666946_Hlymphocyte percentage of leukocytes QTL GWAS666946 (human)6e-92lymphocyte percentage of leukocytesblood lymphocyte count to total leukocyte count ratio (CMO:0000371)47409733274097333Human
407100375GWAS749351_Hmitochondrial DNA measurement QTL GWAS749351 (human)6e-25mitochondrial DNA measurement47409733274097333Human
406966775GWAS615751_Heosinophil percentage of granulocytes QTL GWAS615751 (human)4e-12eosinophil percentage of granulocytes47409733274097333Human
406964008GWAS612984_Hneutrophil percentage of granulocytes QTL GWAS612984 (human)8e-17neutrophil percentage of granulocytes47409733274097333Human
407330525GWAS979501_Hleukocyte count QTL GWAS979501 (human)5e-08leukocyte quantity (VT:0000217)white blood cell count (CMO:0000027)47409715874097159Human
407246669GWAS895645_Hbasophil count QTL GWAS895645 (human)1e-21basophil quantity (VT:0002607)blood basophil count (CMO:0000034)47409733274097333Human
407008398GWAS657374_Hneutrophil count QTL GWAS657374 (human)9e-325neutrophil quantity (VT:0000222)blood neutrophil count (CMO:0000030)47409733274097333Human
407115097GWAS764073_Hneutrophil percentage of leukocytes QTL GWAS764073 (human)4e-126neutrophil percentage of leukocytesblood neutrophil count to total leukocyte count ratio (CMO:0000370)47409733274097333Human
407243320GWAS892296_Hneutrophil-to-lymphocyte ratio QTL GWAS892296 (human)4e-36neutrophil-to-lymphocyte ratio47409733274097333Human
407052940GWAS701916_Hbasophil percentage of leukocytes QTL GWAS701916 (human)3e-19basophil percentage of leukocytesblood basophil count to total leukocyte count ratio (CMO:0000368)47409733274097333Human

Markers in Region
CXCL2_1876  
Human AssemblyChrPosition (strand)SourceJBrowse
GRCh37474,962,712 - 74,963,418UniSTSGRCh37
Build 36475,181,576 - 75,182,282RGDNCBI36
Celera472,322,797 - 72,323,505RGD
HuRef470,773,617 - 70,774,327UniSTS
D4S2819  
Human AssemblyChrPosition (strand)SourceJBrowse
GRCh37474,963,353 - 74,963,472UniSTSGRCh37
GRCh37474,736,254 - 74,736,373UniSTSGRCh37
Build 36474,955,118 - 74,955,237RGDNCBI36
Celera472,323,440 - 72,323,559UniSTS
Celera472,096,382 - 72,096,501RGD
Cytogenetic Map4q21UniSTS
HuRef470,547,393 - 70,547,512UniSTS
HuRef470,774,262 - 70,774,381UniSTS
GeneMap99-GB4 RH Map4424.58UniSTS
Whitehead-RH Map4479.8UniSTS
Whitehead-YAC Contig Map4 UniSTS
NCBI RH Map4875.8UniSTS
SHGC-67843  
Human AssemblyChrPosition (strand)SourceJBrowse
GRCh37474,962,823 - 74,962,959UniSTSGRCh37
Build 36475,181,687 - 75,181,823RGDNCBI36
Celera472,322,908 - 72,323,044RGD
Cytogenetic Map4q21UniSTS
HuRef470,773,728 - 70,773,864UniSTS
GeneMap99-GB4 RH Map4424.53UniSTS
D4S3343  
Human AssemblyChrPosition (strand)SourceJBrowse
GRCh37474,963,176 - 74,963,425UniSTSGRCh37
Build 36475,182,040 - 75,182,289RGDNCBI36
Celera472,323,261 - 72,323,512RGD
Cytogenetic Map4q21UniSTS
HuRef470,774,081 - 70,774,334UniSTS
RH17698  
Human AssemblyChrPosition (strand)SourceJBrowse
GRCh37474,962,938 - 74,963,091UniSTSGRCh37
GRCh37474,736,628 - 74,736,783UniSTSGRCh37
Build 36474,955,492 - 74,955,647RGDNCBI36
Celera472,323,023 - 72,323,176UniSTS
Celera472,096,756 - 72,096,911RGD
Cytogenetic Map4q21UniSTS
HuRef470,547,767 - 70,547,922UniSTS
HuRef470,773,843 - 70,773,996UniSTS
GeneMap99-GB4 RH Map4425.86UniSTS
RH69945  
Human AssemblyChrPosition (strand)SourceJBrowse
GRCh37474,964,546 - 74,964,668UniSTSGRCh37
Build 36475,183,410 - 75,183,532RGDNCBI36
Celera472,324,633 - 72,324,755RGD
Cytogenetic Map4q21UniSTS
HuRef470,775,455 - 70,775,577UniSTS
GeneMap99-GB4 RH Map4425.68UniSTS


Expression

RNA-SEQ Expression

adipose tissue
alimentary part of gastrointestinal system
appendage
circulatory system
ectoderm
endocrine system
endoderm
entire extraembryonic component
exocrine system
hemolymphoid system
hepatobiliary system
integumental system
mesenchyme
mesoderm
musculoskeletal system
nervous system
pharyngeal arch
renal system
reproductive system
respiratory system
sensory system
visual system
1204 2435 2787 2234 4944 1723 2327 5 622 1501 463 2257 6859 6035 42 3707 1 841 1731 1595 174 1

Sequence


Ensembl Acc Id: ENST00000296031
Type: CODING
Position:
Human AssemblyChrPosition (strand)Source
GRCh38.p14 Ensembl474,097,676 - 74,099,195 (-)Ensembl
Ensembl Acc Id: ENST00000508487   ⟹   ENSP00000427279
Type: CODING
Position:
Human AssemblyChrPosition (strand)Source
GRCh38.p14 Ensembl474,097,040 - 74,099,195 (-)Ensembl
Ensembl Acc Id: ENST00000510048
Type: CODING
Position:
Human AssemblyChrPosition (strand)Source
GRCh38.p14 Ensembl474,098,531 - 74,099,196 (-)Ensembl
RefSeq Acc Id: NM_002089   ⟹   NP_002080
RefSeq Status: REVIEWED
Type: CODING
Position:
Human AssemblyChrPosition (strand)Source
GRCh38474,097,040 - 74,099,195 (-)NCBI
GRCh37474,962,752 - 74,964,997 (-)ENTREZGENE
Build 36475,181,616 - 75,183,861 (-)NCBI Archive
HuRef470,773,657 - 70,775,906 (-)ENTREZGENE
CHM1_1474,998,593 - 75,000,838 (-)NCBI
T2T-CHM13v2.0477,440,641 - 77,442,796 (-)NCBI
Sequence:
RefSeq Acc Id: NP_002080   ⟸   NM_002089
- Peptide Label: precursor
- UniProtKB: Q6FGD6 (UniProtKB/Swiss-Prot),   Q9UPB8 (UniProtKB/Swiss-Prot),   P19875 (UniProtKB/Swiss-Prot)
- Sequence:
Ensembl Acc Id: ENSP00000427279   ⟸   ENST00000508487

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-P19875-F1-model_v2 AlphaFold P19875 1-107 view protein structure

Promoters
RGD ID:6867722
Promoter ID:EPDNEW_H7026
Type:initiation region
Name:CXCL2_1
Description:C-X-C motif chemokine ligand 2
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Alternative Promoters:null; see alsoEPDNEW_H7027  
Experiment Methods:Single-end sequencing.
Position:
Human AssemblyChrPosition (strand)Source
GRCh38474,099,195 - 74,099,255EPDNEW
RGD ID:6867724
Promoter ID:EPDNEW_H7027
Type:initiation region
Name:CXCL2_2
Description:C-X-C motif chemokine ligand 2
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Alternative Promoters:null; see alsoEPDNEW_H7026  
Experiment Methods:Single-end sequencing.
Position:
Human AssemblyChrPosition (strand)Source
GRCh38474,099,324 - 74,099,384EPDNEW
RGD ID:6812495
Promoter ID:HG_ACW:59654
Type:CpG-Island
SO ACC ID:SO:0000170
Source:MPROMDB
Tissues & Cell Lines:K562
Transcripts:CXCL2.FAPR07-UNSPLICED
Position:
Human AssemblyChrPosition (strand)Source
Build 36475,182,401 - 75,182,901 (-)MPROMDB
RGD ID:6802190
Promoter ID:HG_KWN:48480
Type:CpG-Island
SO ACC ID:SO:0000170
Source:MPROMDB
Tissues & Cell Lines:HeLa_S3,   K562,   NB4
Transcripts:ENST00000395761,   NM_002089
Position:
Human AssemblyChrPosition (strand)Source
Build 36475,183,766 - 75,184,266 (-)MPROMDB

Additional Information

Database Acc Id Source(s)
AGR Gene HGNC:4603 AgrOrtholog
COSMIC CXCL2 COSMIC
Ensembl Genes ENSG00000081041 Ensembl, ENTREZGENE, UniProtKB/Swiss-Prot
Ensembl Transcript ENST00000508487 ENTREZGENE
  ENST00000508487.3 UniProtKB/Swiss-Prot
Gene3D-CATH 2.40.50.40 UniProtKB/Swiss-Prot
GTEx ENSG00000081041 GTEx
HGNC ID HGNC:4603 ENTREZGENE
Human Proteome Map CXCL2 Human Proteome Map
InterPro Chemokine_b/g/d UniProtKB/Swiss-Prot
  Chemokine_CXC UniProtKB/Swiss-Prot
  Chemokine_CXC_CS UniProtKB/Swiss-Prot
  Chemokine_IL8-like_dom UniProtKB/Swiss-Prot
  CXC_Chemokine_domain UniProtKB/Swiss-Prot
  Interleukin_8-like_sf UniProtKB/Swiss-Prot
KEGG Report hsa:2920 UniProtKB/Swiss-Prot
NCBI Gene 2920 ENTREZGENE
OMIM 139110 OMIM
PANTHER C-X-C MOTIF CHEMOKINE 2 UniProtKB/Swiss-Prot
  SMALL INDUCIBLE CYTOKINE A UniProtKB/Swiss-Prot
Pfam IL8 UniProtKB/Swiss-Prot
PharmGKB PA35051 PharmGKB
PRINTS INTERLEUKIN8 UniProtKB/Swiss-Prot
  SMALLCYTKCXC UniProtKB/Swiss-Prot
PROSITE SMALL_CYTOKINES_CXC UniProtKB/Swiss-Prot
SMART SCY UniProtKB/Swiss-Prot
Superfamily-SCOP SSF54117 UniProtKB/Swiss-Prot
UniProt CXCL2_HUMAN UniProtKB/Swiss-Prot, ENTREZGENE
  Q6FGD6 ENTREZGENE
  Q9UPB8 ENTREZGENE
UniProt Secondary Q6FGD6 UniProtKB/Swiss-Prot
  Q9UPB8 UniProtKB/Swiss-Prot


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2016-03-07 CXCL2  C-X-C motif chemokine ligand 2    chemokine (C-X-C motif) ligand 2  Symbol and/or name change 5135510 APPROVED